Pfizer has announced the successful completion of its acquisition of Metsera.
The acquisition marks the culmination of a protracted and closely watched negotiation process that has garnered significant industry attention in recent months.
The deal ends a period marked by rising investor interest, strategic manoeuvring and speculation over Metsera’s valuation and future direction.
With the transaction now finalised, Pfizer moves to integrate Metsera’s metabolic-disease pipeline and platform technologies.
“This strategic milestone represents more than a transaction — it's a deliberate investment in the future of medicine," said Albert Bourla, Pfizer Chair and CEO.
"By acquiring Metsera, we are directing our resources toward one of the most impactful and high-growth therapeutic areas and positioning ourselves to define it."
"We look forward to combining Metsera’s innovative portfolio with our global development, manufacturing and commercial infrastructure."
"Working with our talented new colleagues from Metsera, we will advance our shared goal of accelerating and bringing these important candidate therapies to patients around the world.”
Through this acquisition, Pfizer has added a portfolio of promising therapeutic candidates that are complementary to Pfizer’s Internal Medicine pipeline.
These include MET-097i, a weekly and monthly injectable GLP-1 receptor agonist (RA) about to begin Phase III development; MET-233i, a monthly amylin analogue candidate being evaluated as monotherapy and in combination with MET-097i in Phase I development; an oral GLP-1 RA candidate in Phase I development and additional preclinical nutrient-stimulated hormone therapeutics.
Additional transaction details
Pfizer has closed its $7bn acquisition of Metsera, comprising $65.60 per share upfront and a further $20.65 per share available through milestone-linked CVRs.
Metsera is now a wholly owned subsidiary of Pfizer.
Its shares of common stock will cease trading on the NASDAQ Global Select Market following the close of the market on Thursday.
The transaction is expected to be dilutive through 2030, primarily to enable further investment in several promising late-stage pipeline candidates.
Updated impact to Pfizer’s financial outlook will be provided in conjunction with its 2026 guidance expected later this year.